Answers are grounded in this paper and cite their sources.
Meta-analysis demonstrates reduced mortality and adverse events in HCC patients with Vitamin K2 supplementation, suggesting good tolerability.
This study suggests substantial benefits associated with VK supplementation in HCC patients, particularly in reducing DR and mortality across one, two, and three years. Importantly, these improvements were achieved without a significant increase in adverse events, indicating good tolerability of VK supplementation in this population.
No takes yet. Share an insight, caveat, or question.
Moraes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: